A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

In studies, many people had reduced symptoms of alopecia areata after 9 months of Olumiant treatment. Your doctor will monitor your condition during your treatment to check whether Olumiant is ...

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

A NEW mum who wanted a new bust after having her baby has lost all of her hair following the operation – including her eyelashes and eyebrows. The silicone implants Czech dental worker ...